Osteoarthritis – opportunity analysis and forecasts to 2024

The Osteoarthritis (OA) market was valued at $3.58 billion within the seven major markets in 2014, and it is expected to increase to $9.22 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The US contributed 68% of the market share in 2014, which is linked to the large OA population and high drug prices in this market. Multiple biologic drug launches are expected during the forecasted period that will lead to a rapid market growth in the US and 5EU, posting CAGRs of 11.1% and 9.2%, respectively.

In contrast, Japan will have the slowest market growth (CAGR of 4.6%), as only one drug is expected to launch in this country during the forecasted period. On the whole, the OA market is largely generalised and no product is anticipated to lose patent protection during the forecasted period.

The current treatments for OA are largely inexpensive generic drugs that have been available for decades. The market suffers from a lack of biologic and disease-modifying drugs, as available therapies offer only symptom relief. However, the OA pipeline is rapidly evolving thanks to improved understanding of the disease’s pathophysiology and recent biomarker development. Current R&D strategies in OA are characterised by a trend towards developing new analgesics with novel MOAs and drugs with disease-modifying effect, reflecting its high market demand.

The site or global license of GlobalData’s report "OpportunityAnalyzer: Osteoarthritis – Opportunity Analysis and Forecasts to 2024", will include an interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy, and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate.